person · Reporting owner
Meyenburg Jason Patrick
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | Director · Chief Executive Officer | January 03, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date January 03, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 123,600 |
Reported balance
After 2022-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 123,600 · Balance 123,600 F1: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock. F2: These Restricted Stock Units shall vest in accordance with certain performance based metrics. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.
F2: These Restricted Stock Units shall vest in accordance with certain performance based metrics.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 30,228 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.65 · Expires 2027-04-03 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 21:08 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantRestricted Stock Units · Derivative | 123,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001634 · doc4.xml · derivative · entry 1 Meyenburg Jason Patrick · CIK 0001709008 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,600 Underlying: Common Stock · 123,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock. F2 · derivative.exercise_date: These Restricted Stock Units shall vest in accordance with certain performance based metrics. F2 · derivative.expiration_date: These Restricted Stock Units shall vest in accordance with certain performance based metrics. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:45 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | PurchaseCommon Stock | 13,000 | $9.46 | $122,929.30 |
DisclosureSEC source: 0000899243-21-019762 · doc4.xml · nonDerivative · entry 1 Meyenburg Jason Patrick · CIK 0001709008 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| February 05, 2021 Filed Apr 7, 2021 20:03 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 1,124,832 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001213900-21-020623 · ownership.xml · derivative · entry 1 Meyenburg Jason Patrick · CIK 0001709008 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,832 Underlying: Common Stock · 1,124,832 shares Expires 2031-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:41 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | $7.35 Strike: $10.65 | $1,102,500.00 |
DisclosureSEC source: 0001171843-18-001100 · f4_meyenburg021318.xml · derivative · entry 2 Meyenburg Jason Patrick · CIK 0001709008 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-04-03 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:41 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerCommon Stock, Class A | 30,228 | $18.00 | $544,104.00 |
DisclosureSEC source: 0001171843-18-001100 · f4_meyenburg021318.xml · nonDerivative · entry 1 Meyenburg Jason Patrick · CIK 0001709008 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 16:40 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | PurchaseCommon Stock, Class A | 4,000 | $12.13 | $48,500.00 |
DisclosureSEC source: 0001171843-17-005464 · formfour.xml · nonDerivative · entry 1 Meyenburg Jason Patrick · CIK 0001709008 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,228 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.